Effects of dark chocolate in a population of normal weight obese women: A pilot study

European Review for Medical and Pharmacological Sciences

Volumn 17, Issue 16, 2013, Pages 2257-2266

  Renzo, L Di ^a,b   Rizzo, M ^a   Sarlo, F ^a   Colica, C ^c   Iacopino, L ^a   Domino, E ^a   Sergi, D ^a   Lorenzo, A De ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b National Institute for Mediterranean Diet and Nutrigenomic   (Italy)

^c UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Atherogenic profile; Dark chocolate; HDL cholesterol; Interleukin 1Ra; Normal weight obese syndrome

Indexed keywords

BIOCHEMICAL MARKER; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ABDOMEN; ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; ATHEROGENESIS; BLOOD PRESSURE; BODY COMPOSITION; BODY WEIGHT; CACAO; CARDIOVASCULAR RISK; CLINICAL ARTICLE; DARK CHOCOLATE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FOOD INTAKE; HIGH RISK PATIENT; HUMAN; INFLAMMATION; MEDITERRANEAN DIET; NORMAL WEIGHT OBESE SYNDROME; NUTRITIONAL ASSESSMENT; OBESITY; PILOT STUDY; PROTEIN BLOOD LEVEL;

ABSORPTIOMETRY, PHOTON; ADULT; ANTHROPOMETRY; BLOOD PRESSURE; BODY MASS INDEX; BODY WEIGHT; CACAO; CANDY; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; CYTOKINES; FEMALE; HUMANS; INFLAMMATION; LIPIDS; OBESITY; PILOT PROJECTS; WAIST CIRCUMFERENCE; YOUNG ADULT;

EID: 84884245193     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. CINTI S. The adipose organ. Prostaglandins Leukot Essent Fatty Acids 2005; 73: 9-15
2. SHAH A, MEHTA N, REILLY MP. Adipose inflammation, insulin resistance, and cardiovascular disease. JPEN J Parenter Enteral Nutr 2008; 32: 638-644
3. DE LORENZO A, MARTINOLI R, VAIA F, DI RENZO L. Normal weight obese (NWO) women: an evaluation of a candidate new syndrome. Nutr Metab Cardiovasc Dis 2006; 16: 513-523
4. DI RENZO L, DEL GOBBO V, BIGIONI M, PREMROV MG, CIANCI R, DE LORENZO A. Body composition analyses in normal weight obese women. Eur Rev Med Pharmacol Sci 2006; 10: 191-196
5. DE LORENZO A, DEL GOBBO V, PREMROV MG, BIGIONI, GALVANO F, DI RENZO L. Normal-weight obese syndrome: early inflammation? Am J Clin Nutr 2007; 85: 40-45
6. DI RENZO L, BIGIONI M, BOTTINI FG, DEL GOBBO V, PREMROV MG, CIANCI R, DE LORENZO A. Normal Weight Obese syndrome: role of single nucleotide polymorphism of IL-1 5Ralpha and MTHFR 677C-T genes in the relationship between body composition and resting metabolic rate. Eur Rev Med Pharmacol Sci 2006; 10: 235-245
7. DI RENZO L, BIGIONI M, DEL GOBBO V, PREMROV MG, BARBINI U, DI LORENZO N, DE LORENZO A. Interleukin-1 (IL-1) Receptor Antagonist Gene Polymorphism in Normal Weight Obese syndrome: Relationship to body composition and IL-1 and plasma levels. Pharmacol Res 2007; 55: 131-138
8. DI RENZO L, BERTOLI A, BIGIONI M, DEL GOBBO V, PREMROV MG, CALABRESE V, DI DANIELE N, DE LORENZO A. Body composition and-174G/C interleukin-6 promoter gene polymorphism: association with progression of insulin resistance in normal weight obese syndrome. Curr Pharm Des 2008; 14: 2699-2706
9. ROMERO-CORRAL A, SOMERS VK, SIERRA-JOHNSON J, KORENFELD Y, BOARIN S, KORINEK J, JENSEN MD, PARATI G, LOPEZJIMENEZ F. Normal weight obesity: a risk factor for cardiometabolic dysregulation and cardiovascular mortality. Eur Heart J 2010; 31: 737-746
10. MARQUES-VIDAL P, PÉCOUD A, HAYOZ D, PACCAUD F, MOOSER V, WAEBER G, VOLLENWEIDER P. Normal weight obesity: relationship with lipids, glycaemic status, liver enzymes and inflammation. Nutr Metab Cardiovasc Dis 2010; 20: 669-675
11. DI RENZO L, GLORIA-BOTTINI F, SACCUCCI P, BIGIONI M, ABENAVOLI L, GASBARRINI G, DE LORENZO A. Role of interleukin-15 receptor alpha polymorphisms in normal weight obese syndrome. Int J Immunopathol Pharmacol 2009; 22: 105-113
12. DI RENZO L, GALVANO F, ORLANDI C, BIANCHI A, DI GIACOMO C, LA FAUCI L, ACQUAVIVA R, DE LORENZO A. Oxidative stress in normal-weight obese syndrome. Obesity (Silver Spring) 2010; 18: 2125-2130
13. MEHRINFAR R, FRISHMAN WH. Flavanol-rich cocoa: a cardioprotective nutraceutical. Cardiol Rev 2008; 16: 109-115
14. CORTI R, FLAMMER AJ, HOLLENBERG NK, LÜSCHER TF. Cocoa and cardiovascular health. Circulation 2009; 119: 1433-1441
15. GRASSI D, DESIDERI G, CROCE G, TIBERTI S, AGGIO A, FERRI C. Flavonoids, vascular function and cardiovascular protection. Curr Pharm Des 2009; 15: 1072-1084
16. DJOUSSÉ L, HOPKINS PN, NORTH KE, PANKOW JS, ARNETT DK, ELLISON RC. Chocolate consumption is inversely associated with prevalent coronary heart disease: The National Heart, Lung, and Blood Institute Family Heart Study. Clin Nutr 2011; 30: 182-187
17. DJOUSSE L. Observational studies find association between chocolate consumption and reduced risk of cardiovascular disease and diabetes. Evid Based Med 2012; 17: 128-129
18. KHAWAJA O, GAZIANO JM, DJOUSSÉ L. Chocolate and coronary heart disease: a systematic review. Curr Atheroscler Rep 2011; 13: 447-452
19. LEWIS JR, PRINCE RL, ZHU K, DEVINE A, THOMPSON PL, HODGSON JM. Habitual chocolate intake and vascular disease: a prospective study of clinical outcomes in older women. Arch Intern Med 2010; 170: 1857-1858
20. DI GIUSEPPE R, DI CASTELNUOVO A, CENTRITTO F, ZITO F, DE CURTIS A, COSTANZO S, VOHNOUT B, SIERI S, KROGH V, DONATI MB, DE GAETANO G, IACOVIELLO L. Regular consumption of dark chocolate is associated with low serum concentrations of C-reactive protein in a healthy Italian population. J Nutr 2008; 138: 1939-1945
21. MONAGAS M, KHAN N, ANDRES-LACUEVA C, CASAS R, URPÍ-SARDÀ M, LLORACH R, LAMUELA-RAVENTÓS RM, ESTRUCH R. Effect of cocoa powder on the modulation of inflammatory biomarkers in subjects at high risk of cardiovascular disease. Am J Clin Nutr 2009; 90: 1144-1150
22. PERSSON IA, PERSSON K, HÄGG S, ANDERSSON RG. Effects of cocoa extract and dark chocolate on angiotensin-converting enzyme and nitric oxide in human endothelial cells and healthy volunteers-a nutrigenomics perspective. J Cardiovasc Pharmacol 2011; 57: 44-50
23. DESCH S, SCHMIDT J, KOBLER D, SONNABEND M, EITEL I, SAREBAN M, RAHIMI K, SCHULER G, THIELE H. Effect of cocoa products on blood pressure: systematic review and meta-analysis. Am J Hypertens 2010; 23: 97-103
24. RIED K, SULLIVAN T, FAKLER P, FRANK OR, STOCKS NP. Does chocolate reduce blood pressure? A metaanalysis. BMC Med 2010; 8: 39
25. DE LORENZO A, ALBERTI A, ANDREOLI A, IACOPINO L, SERRANÒ P, PERRIELLO G. Food habits in a southern Italian town (Nicotera) in 1960 and 1996: still a reference Italian Mediterranean diet? Diabetes Nutr Metab 2001; 14: 121-125
26. FIDANZA F, ALBERTI A, FRUTTINI D. The nicotera diet: the reference Italian Mediterranean diet. World Rev Nutr Diet 2005; 95: 1115-1121
27. DE LORENZO A, TAGLIABUE A, ANDREOLI A, TESTOLIN G, COMELLI M, DEURENBERG P. Measured and predicted resting metabolic rate in Italian males and females, aged 18-59 y. Eur J Clin Nutr 2001; 55: 208-214
28. A. DE LORENZO, A. NOCE, M. BIGIONI, V. CALABRESE, D.G. DELLA ROCCA, N. DI DANIELE, C. TOZZO, LAURA DI RENZO. The Effects of Italian Mediterranean Organic Diet (IMOD) on Health Status. Curr Pharm Des 2010; 16: 814-824
29. SOCIETA ITALIANA DI NUTRIZIONE UMANA (SINU). Livelli di assunzione raccomandata di energia e nutrienti per la popolazione italiana (LARN). Litotipografia Zesi S.r.l. Roma, 1996
30. LOHMAN TG, ROCHE AF, MARTORELL R. Anthropometric standardization reference manual: Human Kinetics, Champaing, IL 1998; pp. 121-133
31. DE LORENZO A, ANDREOLI A, CANDELORO N. Withinsubject variability in body composition using dualenergy X-ray absorptiometry. Clin Physiol 1997; 17: 383-384
32. MILLÁN J, PINTÓ X, MUÑOZ A, ZÚÑIGA M, RUBIÉS-PRAT J, PALLARDO LF, MASANA L, MANGAS A, HERNÁNDEZ-MIJARES A, GONZÁLEZ-SANTOS P, ASCASO JF, PEDRO-BOTET J. Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention. Vasc Health Risk Manag 2009; 5: 757-765
33. EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497
34. EUROPEAN HEART NETWORK. Cardiovascular disease statistics Available from: http://www.ehnheart.org (2008 edition)
35. KARELIS AD, ST PIERRE DH, CONUS F, LHORET RR, POEHLMAN ET. Metabolic and body composition factors in subgroups of obesity: what do we do? J Clin Endocrinol Metab 2004; 89: 2569-2575
36. Ruderman NB, Chisholm D, Pi-Sunier X, Schneider S. The metabolically preobese-obese normal weight revisited. Diabetes 1998; 47: 699-713
37. MURSU J, VOUTILAINEN S, NURMI T, RISSANEN TH, VIRTANEN JK, KAIKKONEN J, NYYSSÖNEN K, SALONEN JT. Dark chocolate consumption increases HDL cholesterol concentration and chocolate fatty acids may inhibit lipid peroxidation in healthy humans. Free Radic Biol Med 2004; 37: 1351-1359
38. BABA S, OSAKABE N, KATO Y, NATSUME M, YASUDA A, KIDO T, FUKUDA K, MUTO Y, KONDO K. Continuous intake of polyphenolic compounds containing cocoa powder reduces LDL oxidative susceptibility and has beneficial effects on plasma HDL-cholesterol concentrations in humans. Am J Clin Nutr 2007; 85: 709-717
39. KRIS-ETHERTON PM, KEEN CL. Evidence that the antioxidant flavonoids in tea and cocoa are beneficial for cardiovascular health. Curr Opin Lipidol 2002; 13: 41-49
40. ENGLER MB, ENGLER MM, CHEN CY, MALLOY MJ, BROWNE A, CHIU EY, KWAK HK, MILBURY P, PAUL SM, BLUMBERG J, MIETUS-SNYDER ML. Flavonoid rich dark chocolate improved endothelial function and increases plasma epicatechin concentrations in healthy adults. J Am Coll Nutr 2004; 23: 197-204
41. SAFEER RS, CORNELL MO. THE EMERGING ROLE OF HDL CHOLESTEROL. Is it time to focus more energy on raising high-density lipoprotein levels? Postgrad Med 2000; 108: 87-90, 93-98
42. MENSINK RP, ZOCK PL, KESTER AD, KATAN MB. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am J Clin Nutr 2003; 77: 1146-1155
43. SERAFINI M, BUGIANESI R, MAIANI G, VALTUENA S, SANTIS SD, CROZIER A. Plasma antioxidants from chocolate. Nature 2003; 424: 1013
44. MELLOR DD, SATHYAPALAN T, KILPATRICK ES, BECKETT S, ATKIN SL. High-cocoa polyphenol-rich chocolate improves HDL cholesterol in Type 2 diabetes subjects. Diabet Med 2010; 27: 1318-1321
45. KAPPELLE PJ, GANSEVOORT RT, HILLEGE JL, WOLFFENBUTTEL BH, DULLAART RP; PREVEND STUDY GROUP. Apolipoprotein B/A-I and total cholesterol/highdensity lipoprotein cholesterol ratios both predict cardiovascular events in the general population independently of nonlipid risk factors, albuminuria and C-reactive protein. J Intern Med 2011; 269: 232-242
46. RIED K, FRANK OR, STOCKS NP. Dark chocolate or tomato extract for prehypertension: a randomized controlled trial. BMC Comp Alternat Med 2009; 9: 22
47. MAO TK, POWELL J, VAN DE WATER J, KEEN CL, SCHMITZ HH, HAMMERSTONE JF, GERSHWIN ME. The effect of cocoa procyanidins on the transcription and secretion of interleukin-1 in peripheral blood mononuclear cells. Life Sci 2000; 66: 1377-1386
48. RAMIRO E, FRANCH A, CASTELLOTE C, PÉREZ-CANO F, PERMANYER J, IZQUIERDO-PULIDO M, CASTELL M. Flavonoids from Theobroma cacao down-regulate inflammatory mediators. J Agric Food Chem 2005; 53: 8506-8511
49. MATHUR S, DEVARAJ S, GRUNDY SM, JIALAL I. Cocoa products decrease low density lipoprotein oxidative susceptibility but do not affect biomarkers of inflammation in humans. J Nutr 2002; 132: 3663-3667
50. ALLEN RR, CARSON LA, KWIK-URIBE C, EVANS EM, ERDMAN JW JR. Daily consumption of a dark chocolate containing flavanols and added sterol esters affects cardiovascular risk factors in a normotensive population with elevated cholesterol. J Nutr 2008; 728: 725-731
51. AREND WP, MALYAK M, GUTHRIDGE CJ, GABAY C. Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 1998; 16: 27-55
52. MEIER CA, BOBBIONI E, GABAY C, ASSIMACOPOULOSJEANNET F, GOLAY A, DAYER JM. IL-1 receptor antagonist serum levels are increased in human obesity: a possible link to the resistance to leptin? J Clin Endocrinol Metab 2002; 87: 1184-1188
53. CARTIER A, BERGERON J, POIRIER P, ALMÉRAS N, TREMBLAY A, LEMIEUX I, DESPRÉS JP. Increased plasma interleukin-1 receptor antagonist levels in men with visceral obesity. Ann Med 2009; 41: 471-478